Recently, CAR-T cell therapy has been approved by the FDA (2020), EMA (2020), and Swissmedic (2021) for patients with relapsed or refractory MCL after two or more lines of systemic therapy, including a BTK inhibitor [28,29,30]. The gene discussed is BTK; the disease is mantle cell lymphoma.